Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 11/20 | 0.76 |
| ▸ | PPARA | Q07869 | 10/20 | 0.76 |
| ▸ | PPARG | P37231 | 15/20 | 0.60 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.60 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1400653 | 1.00 | PPARD (0.76) | PPARDPPARAPPARGNR1H2NR1H3 | |
| SCHEMBL1400433 | 1.00 | PPARD (0.76) | PPARDPPARAPPARGNR1H2NR1H3 | |
| SCHEMBL12798808 | 1.00 | PPARD (0.76) | PPARDPPARAPPARGNR1H2NR1H3 | |
| SCHEMBL20212683 | 1.00 | PPARD (0.76) | PPARDPPARAPPARGNR1H2NR1H3 | |
| SCHEMBL1400427 | 0.94 | PPARD (0.72) | PPARDPPARAPPARGNR1H2NR1H3 | |
| SCHEMBL1400733 | 0.94 | PPARD (0.72) | PPARDPPARAPPARGNR1H2NR1H3 | |
| SCHEMBL20222430 | 0.90 | PPARD (0.63) | PPARDPPARAPPARGNR1H2NR1H3 | |
| SCHEMBL10216246 | 0.89 | PPARD (0.75) | PPARDPPARAPPARGNR1H2NR1H3 | |
| SCHEMBL15627370 | 0.89 | PPARD (0.75) | PPARDPPARAPPARGNR1H2NR1H3 | |
| SCHEMBL10216248 | 0.89 | PPARD (0.75) | PPARDPPARAPPARGNR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | CHAT, ACHE, CHRNA2 | PPARD 1188/4885PPARA 516/4885PPARG 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.